Retrotope’s RT001 Receives EMA’s Orphan Drug Designation for Infantile Neuroaxonal Dystrophy (INAD)

Shots:

• The EMA’s ODD is based on P-II/III study assessing RT001 in patients with INAD, a neurodegeneration associated with PLA2G6
• EMA’s ODD is granted to the drug offering treatments for rare, devastating, fatal, and untreated diseases affecting fewer than 200,000 people or >200,000 persons
• Retrotope’s RT001 is an oral deuterated polyunsaturated fatty acid (D-PUFA) working against PUFA to prevent cell death

Click here to read full press release/ article | Ref: Retrotope | Image: PRNewswire